Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes

PURPOSE: We set out to determine whether clinically tested epigenetic drugs against class I histone deacetylases (HDACs) affect hallmarks of the metastatic process. METHODS: We treated permanent and primary renal, lung, and breast cancer cells with the class I histone deacetylase inhibitors (HDACi)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiweler, Nicole, Wünsch, Désirée, Wirth, Matthias, Mahendrarajah, Nisintha, Schneider, Günter, Stauber, Roland H., Brenner, Walburgis, Butter, Falk, Krämer, Oliver H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985217/
https://www.ncbi.nlm.nih.gov/pubmed/31932908
http://dx.doi.org/10.1007/s00432-019-03118-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985217/
https://www.ncbi.nlm.nih.gov/pubmed/31932908
http://dx.doi.org/10.1007/s00432-019-03118-4

Ejemplares similares